An analysis of causes for the discontinuation of a simplified antiretroviral regimen with abacavir, lamivudine and zidovudine;Análisis de las causas de suspensión del régimen antirretroviral simplificado abacavir, lamivudina y zidovudina

Farmacia Hospitalaria

Volumn 29, Issue 3, 2005, Pages 164-170

  Morillo Verdugo, Ramón ^a,b   Abdel Kader Martin L ^a   Marquez Saavedra E ^a   Martinez Alonso I ^a   Artacho Criado, S ^a   Almeida Gonzalez C ^a   Miguel Del Corral, M ^a  

^a HOSPITAL UNIVERSITARIO DE VALME   (Spain)

^b NONE   (Spain)

Author keywords

Abacavir; Adherence; Discontinuation; Lamivudine; Na ve; Zidovudine

Indexed keywords

ABACAVIR PLUS LAMIVUDINE PLUS ZIDOVUDINE; ANTIRETROVIRUS AGENT;

ARTICLE; CONTROLLED STUDY; DRUG ABUSE; FEMALE; HUMAN; HYPERSENSITIVITY REACTION; KAPLAN MEIER METHOD; MALE; TREATMENT WITHDRAWAL; VIRUS INFECTION; VIRUS LOAD;

EID: 23644442909     PISSN: 11306343     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1130-6343(05)73658-8     Document Type: Article

References (30)

1. Iribarren JA, Labarga P, Rubio R, Berenguer J, Miro JM, Antela A, et al. Recomendaciones de GESIDA/PNS respecto al tratamiento antirretroviral en pacientes adultos infectados por el virus de la inmunodeficiencia humana (octubre 2004). Enferm Infecc Microbiol Clin 2004; 22: 564-642.
2. Escobar I, Knobel H, Polo R, Ortega L, Martin-Conde MT, Casado JL, et al. Recomendaciones GESIDA/SEFH/PNS para mejorar la adherencia al tratamiento antirretroviral en el año 2004. Farm Hosp 2004 (Supl. 1):6-18.
3. Panel of Clinical Practices for Treatment of HIV infection convened by the Department of Health and Human Services (DHHS). Guidelines for the Use of Antirretroviral Agents in HIV-1-Infected Adults and Adolescents. October, 29, 2004. scentswww.aidsinfo.nih.gov/ guidelines/adult/AA_102904.pdf.
4. Paul S, Gilbert HM, Ziecheck W, Jacobs J, Sepkowitz KA. The impact of potent antiretroviral therapy on the characteristics of hospitalized patients with HIV infection. AIDS 1999; 13: 415-8.
5. Palella FJ, Delaney KM, Moorman AC, Loveless MO, Fuhrer J, Satten GA, et al. Declining morbidity an mortality among patients with advanced human immunodeficiency virus infection. HIV Outpatient Study Investigators. N Engl J Med 1998; 338: 853-60.
6. Paterson DL, Swindells S, Mohr J, Brester M, Vergis EN, Squier C, et al. Adherence to protease inhibitor therapy and outcomes in patients with HIV infection. Ann Intern Med 2000; 133: 21-30.
7. Mocroft A, Vella S, Benfield TL, Chiesi A, Miller V, Gargalianos P, et al. Changing patterns of mortality across Europe in patient infected with HIV-1. EuroSIDA study group. Lancet 1998; 352: 1725-30.
8. Vittinghoff E, Scheer S, O'Malley P, Colfax G, Holmberg SD, Buchbinder SP, et al. Combination antiretroviral therapy and recent declines in AIDS incidence and mortality. J Infect Dis 1999; 179: 717-20.
9. Mocroft A, Youle M, Moore A, Sabin C, Madge S, Cozzi A, et al. Reasons for modification and discontinuation of antiretrovirals: result from a single treatment centre. AIDS 2001; 15: 185-94.
10. D'arminio A, Cozzi A, Rezza G, Pezzotti P, Antinori A, Phillips A, et al. Insights into the reasons for discontinuation of the first highly active antiretroviral therapy (HAART) regimen in a cohort of antiretroviral naive patients. AIDS 2000; 14: 499-507.
11. Katlama C, Fenske S, Gazzard B, Lazzarin A, Clumeck N, Mallolas J, et al. TRIZAL study: switching from successful HAART to Trizivir (abacavir-lamivudine- zidovudine combination tablet): 48 weeks efficacy, safety and adherence results. HIV Med 2003; 4: 79-86.
12. Clumeck N, Goebel F, Rozenbaum W, Gerstoft J, Staszewski S, Montaner J, et al. Simplification with abacabir-based triple nucleoside therapy versus continued PI-based HAART in HIV-1infected patients with undetectable plasma HIV-1 RNA. AIDS 2001; 15: 1517-26.
13. Seaton R, Fox R, Bodasing N, Peters E, Gourlay Y. Effect of co-formulated zidovudine, lamivudine and abacavir (Trizivir) on antiretroviral-naive patients presenting with advanced HIV-1 infection. AIDS 2003; 17: 445-53.
14. Descamps D, Flandre P, Calvez V, Peytavin G, Meiffredy V, Collin G, et al. Mechanisms of virologic failure in previously untreated HIV-infected patients from a trial of induction-maintenance therapy. JAMA 1999; 283: 205-11.
15. Havlir D, Hellman N, Petropoulos C, Whitcomb J, Collier A, Hirsch M, et al. Drug susceptibility in HIV infection after viral rebound in patients receiving indinavir-containing regimens. JAMA 1999; 283: 229-34.
16. Matheron S, Descamps D, Boue F, Livrozet JM, Lafeuillade A, Aquilina C, et al. Triple nucleoside combination zidovudine/lamivudine/abacavir versus zidovudine/lamivudine/nelfinavir as first-line therapy in HIV-1-infected adults: a randomized trial. Antivir Ther 2003; 8: 163-71.
17. Hetterington S, McGuirk S, Powell G, Cutrell A, Naderer O, Spreen B, et al. Hypersensitivity reactions during therapy with the nucleoside reverse transcriptase inhibitor abacavir. Clin Ther 2001; 23: 1603-14.
18. Kitahata MM, Reed SD, Dillinghan PW, Van Rompaey SE, Young A, Harrington RD, et al. Pharmacy-based assessment of adherence to HAART predict virologic and immunologic treatment response and clinical progression to AIDS and death. Int J STD AIDS 2004; 15: 803-10.
19. Ait-khaled M, Abdelrahim R, Griffin P, Cutrell A, Fischl M, Clumeck N, et al. Mutations in HIV-1 reverse transcriptase during therapy with abacavir, lamivudine and zidovudine in HIV-1 infected adults with no prior antiretroviral therapy. Antivir Ther 2002; 7: 43-51.
20. Opravil M, Hirschel B, Lazzarin A, Furrer H, Chave JP, Yerli S, et al. A randomized trial of simplified maintenance therapy with abacavir, lamivudine, and zidovudine in human immunodeficiency virus infection. J Infect Dis 2002; 185: 1251-60.
21. Staszewski S, Keiser P, Montaner J, Raffi F, Gathe J, Brotas V, et al. Abacavir-lamivudine-zidovudine vs indinavir-lamivudine-zidovudine in antiretroviral-naive HIV infected adults. JAMA 2001; 285: 1155-63.
22. Moyle GJ, Gazzard BG. Switching to zidovudine plus lamivudine plus abacavir maintains viral supression in patients with high viral load before antiretroviral therapy retrospective clinical cohort analysis. AIDS 2002; 3: 1086-7.
23. Katlama C, Gazzard B, Mallolas J, Schurmann D, Moroni M, Demonty N, et al. Comparison of metabolic abnormalities 48 weeks after switching from higly active antiretroviral therapy containing a non-nucleoside reverse transcriptase inhibitor to Trizivir versus continued higly active antiretroviral therapy. AIDS 2003; 17: 1855-6.
24. Lafeuillade A, Clumeck N, Mallolas J, Jaeger H, Livrozet J, Ferreira S, et al. Comparison of metabolic abnormalities and clinical lipodystrophy 48 weeks after switchin from HAART to Trizivir versus continued HAART: the Trizal study. HIV Clin Trials 2003; 4: 37-43.
25. Clotet B, Carmena J, Pulido F, Luque I, Rodríguez-Alcántara F, COL30494 Cohort Study Members. Adherence, quality of life, and general satisfaction with co-formulated zidovudine, lamivudine, and abacavir on antiretroviral-experienced patients. HIV Clin Trials 2004; 5: 33-9.
26. Knobel H, Vallecillo G, Guelar A, Pedrol E, Soler A, Carmona A, et al. Simplified therapy with zidovudine, lamivudine, and abacavir for very nonadherent treatment-failing patients. HIV Clin Trials 2004; 5: 65-73.
27. Ibarra O, Martínez MJ, Illaro A, Lertxundi U, Iglesias A, Santos A. Simplificación con lamivudina, zidovudina y abacavir: repercusión sobre la adherencia, resultados clínicos e impacto económico. Farm Hosp 2004 (Supl. 1): 27-33.
28. Knobel H, Guelar A. Estrategias para optimizar la adherencia al tratamiento antirretroviral. Intervenciones en la pauta terapéutica. Enferm Infecc Microbiol Clin 2004; 22: 106-12.
29. Martín V, Ortega L, Pérez MR, Mostaza JL, Ortiz de Urbina J, Rodríguez M, et al. Factores predictores de no adherencia al tratamiento antirretroviral de gran actividad. Enferm Infecc Microbiol Clin 2002; 20: 491-7.
30. Cahn P, Vibhagool A, Schechter M, Soto L, Carosi G, Smaill F, et al. Predictors of adherence and virologic outcome in HIV-infected patients treated with abacavir- or indinavir-based triple combination HAART also containing lamivudine/zidovudine. Curr Med Res Opin 2004; 20: 1115-23.